#1 Clinical Trials Search in Europe

Topotecan Hydrochloride

Topotecan hydrochloride is a chemotherapy drug that has been the subject of numerous clinical trials for various types of cancer. These trials aim to evaluate its effectiveness, safety, and optimal dosing regimens in treating conditions such as ovarian cancer, cervical cancer, leukemia, and other malignancies. Researchers are exploring topotecan hydrochloride both as a single agent and in combination with other drugs to improve outcomes for patients with difficult-to-treat cancers.

Table of Contents

What is Topotecan Hydrochloride?

Topotecan Hydrochloride, also known by its brand names Hycamtin, Brakiva, or simply referred to as topotecan, is a chemotherapy drug used to treat various types of cancer[1]. It is a semi-synthetic derivative of camptothecin, which is a substance originally isolated from a Chinese tree called Camptotheca acuminata[2]. Topotecan belongs to a class of drugs known as topoisomerase I inhibitors, which means it works by interfering with the DNA replication process in cancer cells.

How Does Topotecan Work?

Topotecan works by inhibiting an enzyme called topoisomerase I. This enzyme is crucial for cancer cells to divide and grow. By blocking this enzyme, topotecan prevents cancer cells from dividing, which ultimately leads to their death[3]. This mechanism of action makes topotecan effective against various types of cancer cells that are rapidly dividing.

What Conditions Does Topotecan Treat?

Topotecan Hydrochloride is used to treat several types of cancer, including:

  • Ovarian Cancer: Particularly in cases where the cancer has returned or persisted after treatment with other chemotherapy drugs[4].
  • Small Cell Lung Cancer: Especially in cases where the cancer has progressed after initial treatment[5].
  • Cervical Cancer: Used in combination with other treatments for advanced stages of cervical cancer[1].
  • Leukemia: Particularly in children with refractory (difficult to treat) leukemia[3].

How is Topotecan Administered?

Topotecan is typically administered intravenously (through a vein) in a hospital or clinic setting. The dosage and frequency of administration can vary depending on the specific condition being treated and the patient’s overall health. Some common administration methods include:

  • 30-minute infusions on days 1, 8, and 15 of a 28-day cycle[6].
  • Continuous infusion over 3-6 weeks, often combined with radiation therapy for certain cancers[5].
  • Daily infusions for 3-5 consecutive days, repeated every 3-4 weeks[7].

Current Clinical Trials

Topotecan is currently being studied in various clinical trials to explore its effectiveness in different cancer types and treatment combinations. Some ongoing research includes:

  • Combining topotecan with other chemotherapy drugs like paclitaxel and cisplatin for ovarian cancer[8].
  • Using topotecan in combination with radiation therapy for cervical cancer[1].
  • Exploring the effectiveness of topotecan in combination with targeted therapies like lapatinib for recurrent ovarian cancer[6].

Potential Side Effects

Like all chemotherapy drugs, topotecan can cause side effects. The most common side effects include:

  • Neutropenia: A decrease in white blood cells, which can increase the risk of infections[2].
  • Anemia: A decrease in red blood cells, which can cause fatigue and shortness of breath.
  • Thrombocytopenia: A decrease in platelets, which can increase the risk of bleeding.
  • Nausea and vomiting
  • Fatigue
  • Hair loss

Your healthcare team will monitor you closely for these side effects and may adjust your treatment plan if necessary.

Combination Therapy

Topotecan is often used in combination with other cancer treatments to enhance its effectiveness. Some common combinations include:

  • Topotecan with radiation therapy for cervical and lung cancers[5].
  • Topotecan with other chemotherapy drugs like cisplatin or paclitaxel for ovarian cancer[8].
  • Topotecan with targeted therapies like lapatinib for recurrent ovarian cancer[6].

Ongoing Research

Researchers continue to explore new ways to use topotecan in cancer treatment. Some areas of ongoing research include:

  • Using topotecan in lower doses to reduce side effects while maintaining effectiveness[2].
  • Combining topotecan with new targeted therapies to improve outcomes in hard-to-treat cancers.
  • Exploring the use of topotecan in other types of cancer not currently approved for treatment.
  • Investigating the potential of topotecan in treating COVID-19 by reducing hypoxia (low oxygen levels) in patients with moderate to severe disease[2].
Aspect Details
Drug Name Topotecan Hydrochloride
Cancer Types Studied Ovarian cancer, cervical cancer, acute myeloid leukemia, chronic myelomonocytic leukemia, myeloproliferative disorders
Administration Methods Intravenous infusion, oral capsules
Common Dosing Schedules Daily for 3-5 days every 3 weeks, or weekly for 3 weeks in a 4-week cycle
Primary Outcomes Measured Tumor response rates, progression-free survival, overall survival
Secondary Outcomes Toxicity profile, quality of life, pharmacokinetics
Combination Therapies Studied with carboplatin, veliparib, and other agents
Special Populations Pediatric patients, platinum-sensitive and platinum-resistant cancers
Safety Monitoring Regular assessment of adverse events, blood counts, and organ function

FAQ

  • What is topotecan hydrochloride? Topotecan hydrochloride is a chemotherapy drug that works by inhibiting an enzyme called topoisomerase I, which is important for cancer cell growth. It is used to treat various types of cancer, including ovarian, cervical, and certain blood cancers.
  • How is topotecan hydrochloride administered? Topotecan hydrochloride can be administered intravenously (through a vein) or orally (by mouth). The method and schedule of administration may vary depending on the specific clinical trial and type of cancer being treated.
  • What types of cancer are being studied with topotecan hydrochloride? Clinical trials are investigating topotecan hydrochloride for various cancers, including ovarian cancer, cervical cancer, acute myeloid leukemia, chronic myelomonocytic leukemia, and other myeloproliferative disorders.
  • Are there any common side effects of topotecan hydrochloride? Common side effects of topotecan hydrochloride may include low blood cell counts (which can increase the risk of infection, bleeding, and fatigue), nausea, vomiting, diarrhea, and hair loss. The severity and frequency of side effects can vary depending on the dosage and individual patient factors.
  • How do researchers determine if topotecan hydrochloride is effective in clinical trials? Researchers assess the effectiveness of topotecan hydrochloride by measuring outcomes such as tumor response rates, progression-free survival, overall survival, and duration of response. They also evaluate the drug's safety profile and compare its performance to standard treatments or placebos.

Ongoing Clinical Trials on Topotecan Hydrochloride

  • Phase 3 Study of INCB123667 versus investigator’s choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Ireland Italy The Netherlands +2

  • Study of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +4

  • Study on Ribociclib, Topotecan, and Temozolomide for Children and Young Adults (12 months – 21 years) with Relapsed or Refractory Neuroblastoma and Solid Tumors

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany Hungary Italy +1

Glossary

  • Topotecan Hydrochloride: A chemotherapy drug that inhibits topoisomerase I, an enzyme involved in DNA replication. It is used to treat various types of cancer.
  • Intravenous (IV): A method of administering medication directly into a vein using a needle or tube.
  • Progression-free Survival: The length of time during and after treatment that a patient lives without the cancer getting worse.
  • Overall Survival: The length of time from the start of treatment or diagnosis that patients are still alive.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment.
  • Myeloproliferative Disorders: A group of blood cancers in which the bone marrow produces too many of certain types of blood cells.
  • Acute Myeloid Leukemia (AML): A type of cancer that affects the blood and bone marrow, characterized by rapid growth of abnormal white blood cells.
  • Chronic Myelomonocytic Leukemia (CMML): A type of cancer that affects blood-forming cells in the bone marrow, leading to an increase in white blood cells called monocytes.
  • Complete Response (CR): The disappearance of all signs of cancer in response to treatment.
  • Partial Response (PR): A decrease in the size of a tumor or in the extent of cancer in the body in response to treatment.
  • RECIST: Response Evaluation Criteria In Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Dose-limiting Toxicity: Side effects of a drug that are severe enough to prevent an increase in dosage or require a reduction in dosage.
  • Minimal Residual Disease (MRD): A small number of cancer cells that remain in the body during or after treatment.

References

  1. https://clinicaltrials.gov/study/NCT00054444
  2. https://clinicaltrials.gov/study/NCT05083000
  3. https://clinicaltrials.gov/study/NCT00002705
  4. https://clinicaltrials.gov/study/NCT01840943
  5. https://clinicaltrials.gov/study/NCT00002537
  6. https://clinicaltrials.gov/study/NCT02569957
  7. https://clinicaltrials.gov/study/NCT00002587
  8. https://clinicaltrials.gov/study/NCT00002913